Seelos Therapeutics, Inc. SEEL Cash Flow

Seelos therapeutics, inc. (SEEL)

CashFlow / Quarterly

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11
Cash flows from operating activities:
Net loss and comprehensive loss
-4,832	-10,659	-3,221	-1,863	-35,512	-1,220	-1,097	-497	-661	-2,446	-3,832	-1,474	8,073	-299	-1,291	-3,338	-2,505	-2,332	-5,034	-5,245	-6,412	-17,288	-3,113	1,877	-3,262	-1,345	-2,985	-3,935	-8,673	-19,637	-2,495	-4,926	-4,713	-4,691	-2,220	-7,794	-3,411
Net income (loss) from discontinued operations
-	-	-	-	-	-	-	-	-	153	177	263	11,477	16	305	-104	9	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gain (loss) from discontinued operations
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	290	214	151	-1,723	-3,902	-573	-574	-1,046	-	-	-	-
Net loss from continuing operations
-	-	-	-	-	-	-	-	-	-2,599	-4,009	-1,737	-3,404	-315	-1,596	-3,234	-2,514	-	-	-	-	-	-	-	-	-1,635	-3,199	-4,086	-6,950	-15,735	-1,922	-4,352	-3,667	-	-	-	-
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization
-	-	-	-	-	-	-	-	-	19	21	21	56	-111	72	73	72	76	75	75	74	68	62	20	20	20	16	20	21	-307	314	98	98	92	91	172	245
Stock-based compensation expense
311	144	133	144	38	-1	3	23	8	235	331	288	284	320	333	739	355	298	298	325	289	275	420	545	491	370	384	797	441	1,195	596	591	535	590	398	526	619
Research and development expensed - license acquired
192	0	0	0	3,000	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Change in fair value of convertible notes payable
0	0	0	0	109	162	-57	49	6	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Change in fair value of warrant liabilities
-654	369	-415	-1,503	18,050	0	0	0	0	58	296	-716	1,008	-2,416	-626	-1,637	-2,800	-1,432	-1,193	-747	136	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Loss on warrant issuance
0	0	0	0	5,020	0	0	0	0	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gain on contract settlement
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-10	0	0	910	0	534	0	0	-	-	-	-	-	-	-	-
Recovery on loss on sale of subsidiary
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	50	75	75	105	0	-	-	-	-	-	-	-	-
Derivative liability revaluation
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-95	-29	-393	31	-132	-256	631	-	-	-	-	-	-	-	-
Loss on debt extinguishment
-	-	-	-	-	-	-	-	-	0	0	0	-422	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Non-cash interest expense
-	-	-	-	-	-	-	-	-	0	0	0	56	80	88	96	98	58	115	36	58	35	22	47	59	58	44	80	68	-	-	-	-	-	-	-	-
Interest on contingent consideration
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	68	84	90	-	-	-	99	-	-	-	-
Other
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	-114	63	-84	4	-	-	-	-	-	-	-	-
Changes in operating assets and liabilities from continuing operations:
(Gain)/loss on disposal/sale of fixed assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-0
Accounts receivable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-56	-89	151	-165	-150	780	-20	10	23	-646	486	-116	-3,173	2,135	-515	871	-107	61	-225	180
Inventories
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	327	-269	194	-58	-46	-56	13	28	3	89	249	0	-	-	-	-	-	-	-	-
Decrease (increase) in other receivable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	114	0	25
Prepaid expenses and other current assets
648	-204	372	-385	903	-110	116	0	0	45	-106	141	4	-151	-39	19	-237	-252	334	161	223	-134	125	370	103	-206	76	-45	32	2	478	358	90	39	93	-110	31
Other assets
-	-	-	-	-	-	-	0	0	0	-11	-18	4	-22	4	174	-196	1	3	6	3	-	-	-	-	53	-1	0	0	-	-	-	42	-	-	-	35
Other assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	12	2	-	-	-	-	-	-	-	-	-	-	-	-
Accounts payable
2,486	-1,053	824	-1,396	201	394	773	112	393	-280	122	-345	-202	-60	-296	350	51	1,052	-1	-374	-68	-361	93	135	67	312	-846	8	-394	402	795	-4	-512	940	-16	-470	535
Deferred revenue - short-term
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	467	-683	-32	-	-	-	-	-	-	-	-
Accrued expenses
-428	1,016	-2,308	780	2,045	74	-51	-46	-73	-98	-105	-957	479	-237	-590	-342	-171	410	338	-2,485	461	2,704	59	-95	-203	-76	-916	533	-17	-1,910	1,122	-615	55	161	-497	1,477	86
Accrued interest
0	1	0	0	12	18	67	27	19	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Licenses payable
-2,850	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred offering costs
-	-	-	-	-	-	-66	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accrued compensation
-	-	-	-	-	-	-	-	-	195	11	-81	124	-42	65	186	-569	344	-41	370	-562	259	95	274	-468	583	-76	-760	113	967	-753	1,039	-286	-	-	-	-
Deferred revenue - long-term
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-
Increase (decrease) in payroll related liabilities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	158	-203
Deferred compensation
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-45	-45	-45	-	-	-	-	-	-	-	-	-	-65	-5	-95	-	-	-	-43	-	-338	304	-17
Deferred revenue
-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-	131	-1,150	-24	-45	-1,058	-716	-3,454	4,654	-	-	-	-	-715	-130	178	177	131	-2	11	-16
Other liabilities
-	-	-	-	-	-	-	-	-	15	-6	-9	-7	-136	-5	-5	25	9	-54	-54	-55	-54	-54	-52	-54	-438	23	161	-3	-174	48	72	51	-	-	-	-
Net cash used in operating activities
-6,423	-5,118	-2,910	-3,337	-7,940	-397	-544	-332	-308	-2,498	-3,222	-3,659	-1,192	-2,599	-2,309	-3,807	-5,065	-	-	-	-	-	-	-	-	825	-4,422	-5,459	-6,047	-2,029	-2,912	-2,960	-4,496	-	-	-	-
Net cash used in operating activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-1,310	-6,594	-8,611	-6,127	-	-	-	-192	-	-	-	-	-	-	-	-	-	-2,789	-2,073	-2,433
Purchase of fixed assets, net
-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	12	6	121	28	23	165	80	68	77	355	454	3	79	37	413	3	0	20	64	21	168	7
Proceeds from sale of subsidiary
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	50	75	75	105	0	-	-	-	-	-	-	-	-
Proceeds from the sale of property and equipment
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	3,657	-	-	-	-	-	-	-	-
Release of restricted cash
-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	180	100	0	0	0	10	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash provided by investing activities from continuing operations
-	-	-	-	-	-	-	-	-	-	-	-	-	3	0	168	94	-	-	-	-	-	-	-	-	-379	72	37	3,329	-1,302	2,688	2	-20	-	-	-	-
Net cash provided by (used in) investing activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-116	-28	-13	-165	-	-	-	-305	-	-	-	-	-	-	-	-	-	-21	-168	-7
Cash flows from financing activities:
Proceeds from issuance of common stock and warrants in a private offering
0	-	-	-	16,520	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from issuance of common stock, pursuant to Securities Purchase Agreement, net of issuance costs
8,850	0	0	16,520	0	-1,265	700	500	65	-	-	-	-	-23	5,180	-342	9,947	0	0	-88	10,957	895	2,842	535	1,641	0	0	15,821	791	921	0	0	19,489	921	2,494	304	2,436
Proceeds from exercise of warrants
0	74	0	1,773	2,670	0	0	0	0	289	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	5	0	35	22	22	423	895
Repayment of notes payable
-	-	-	-	-	-	-	-	-	0	0	0	7,129	802	785	771	755	495	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from the exercise of stock options
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	83	0	0	0	0	-	-	-	-	0	0	0	10	-	-	-	-
Net cash provided by financing activities
8,850	64	8,497	1,773	19,190	100	700	500	65	-	-	-	-	-	-	-	-	-496	4,998	-99	11,048	-	-	-	1,583	-	-	-	-	-	-	-	-	-	2,549	1,207	3,470
Release (deposit) of restricted cash
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	50	-	0	-11	291	-	-	-	-	-	-	-	-
Repayment of short-term borrowing
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	216	185
Repayment of capital lease obligations
-	-	-	-	-	-	-	-	-	-	-	-	-	0	2	2	1	1	2	1	2	2	8	9	8	-8	10	25	0	-	-	-	-	4	0	13	1
Deposit of restricted cash
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-1	20	209	325
Net cash provided by financing activities from continuing operations
-	-	-	-	-	-	-	-	-	-	-	6,078	-7,129	-825	3,752	-1,115	9,191	-	-	-	-	-	-	-	-	8	-10	15,842	791	1,230	4	-2	19,534	-	-	-	-
Cash flows from discontinued operations:
Net cash (used in) provided by operating activities of discontinued operations
-	-	-	-	-	-	-	-	-	25	194	1,390	-1,504	-106	1,448	570	-1,200	-	-	-	-	-	-	-	-	182	215	366	-725	-706	14	-629	-664	-	-	-	-
Net cash provided by investing activities of discontinued operations
-	-	-	-	-	-	-	-	-	-	-	250	11,500	0	0	0	0	-	-	-	-	-	-	-	-	150	0	0	1,500	960	-1,000	0	-260	-	-	-	-
Net cash provided by (used in) discontinued operations
-	-	-	-	-	-	-	-	-	234	444	1,640	9,996	-106	1,448	570	-1,200	-	-	-	-	-	-	-	-	332	215	366	775	254	-986	-629	-924	-	-	-	-
Effect of exchange rate changes on cash
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	126	-	-	-	-	-	-	-	-
Net increase in cash
2,427	-5,054	5,587	-1,564	11,250	-297	156	168	-243	-2,132	642	4,059	1,675	-3,527	2,891	-4,184	3,020	-1,922	-1,624	-8,723	4,756	-4,709	-1,311	-5,071	1,086	786	-4,145	10,660	-1,026	-1,731	-1,079	-3,589	14,094	-1,443	-262	-1,034	1,029
Supplemental disclosure of cash flow information:
Cash paid for interest
-	-	-	-	-	-	-	-	-	-	-	0	92	138	154	169	185	-	-	-	-	-	-	-	-	-	-	-	-	95	149	0	74	158	0	88	85
Cash paid for interest
4	0	5	6	5	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash paid for income taxes
0	0	0	0	0	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Non-cash investing and financing activities:
Issuance of common stock for conversion of debt and accrued interest
0	-	0	165	2,550	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Issuance of common stock for conversion of accrued interest
0	0	0	0	164	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Effect of reverse merger
0	0	0	0	299	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Reclass of warrant liabilities related to Series A warrants exercised for cash
0	96	0	1,848	3,656	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Reclass of Series B warrants from warrant liability to stockholders' equity
0	0	0	0	31,473	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Transaction costs for 2018 financing activities
-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Transaction costs for 2016 financing activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Capital lease payable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Purchase of fixed assets not yet paid
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	12	-	-	-	0	-	-	-70	70	-	-	-	-	-	-	-	-	-	-	-	-
Liabilities incurred in connection with the purchase of fixed assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-
Accrued transaction costs for 2016 financing activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	137	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-
Issuance of placement agent warrants
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	42	-	-	-	-	-	-	-	-	-	-	-	-
Reclassification of warrant liabilities to equity
-	-	-	-	-	-	-	-	-	0	0	798	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Issuance of restricted stock
-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	249	0	0	0	0	-	-	-	-	-	-	-	133	-	-	-	-	-	-	-	-
Accrued transaction costs for financing activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-60	88	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-